RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--May 31, 2006--Icagen, Inc. (NASDAQ: ICGN - News) today announced that a safety, pharmacokinetics and pharmacodynamics study of ICA-17043 in pediatric sickle cell disease patients has been initiated. This pediatric study will be an open label, parallel group trial involving a total of 28 patients, ages six to 16, and will be conducted at up to eight academic medical centers across the U.S.
